Cancer Immunology, Immunotherapy

, Volume 33, Issue 6, pp 411–416 | Cite as

Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin

  • E. C. De Boer
  • W. H. De Jong
  • A. P. M. Van Der Meijden
  • P. A. Steerenberg
  • J. A. Witjes
  • P. D. J. Vegt
  • F. M. J. Debruyne
  • E. J. Ruitenberg
Original articles

Summary

To study the mode of action of intravesical bacillus Calmette-Guérin (BCG) immunotherapy in the prevention and cure of superficial bladder cancer, flow-cytofluorometric analysis of the cellular immunological reaction in the urine of patients was performed. Fresh urinederived leucocytes were obtained from eight patients before (t0) and 24 h (t24) and 48 h (t48) after repeated intravesical BCG instillations (at least 5 instillations). For two patients urine-derived leucocytes were investigated at the first BCG instillation. The number of leucocytes in the urine was markedly increased 24 h after repeated BCG instillations, indicating a local cellular immunological reaction induced by BCG. The mean number of cells per milliliter of urine at that time was 2.9×106±3.6×106 (n = 8). These leucocytes consisted mainly of granulocytes (75±11%,n = 8). In addition monocytes/macrophages (4±2%,n = 8) and T lymphocytes were present (1±1%,n = 5). The relative increase of monocytes/macrophages in the urine after BCG application tended to be higher compared to the other leucocyte subtypes. As T lymphocytes may play an important role in the BCG-mediated antitumour activity, subsets of lymphocytes were further characterized att0,t24, andt48 after repeated BCG instillations. The lymphocyte population consisted mainly of T cells (86% CD3+,t0). Most of the T cells were CD4+ (helper/inducer) and were significantly decreased at 48 h (62±9% att0 vs 49±6% att48). Lymphocytes partly expressed HLA-DR antigens (44%,t0). The percentage of lymphocytes with interleukin-2 (IL-2) receptors (CD25+) was significantly increased at 24 h and 48 h, compared to pre-instillation values (19±11% and 10±4% vs 3±3% respectively). Natural killer cells (CD 16+ and/or CD56+) and B cells (CD 19+) were less numerous (10% and 19% att0 respectively). After the first BCG instillation the increase in the number of leucocytes in urine seemed to be less compared to the numbers after repeated BCG instillations. Lymphocytes could not be detected in the urine collected before or after the first BCG instillation. In conclusion, we demonstrated the presence of considerable numbers of leucocytes in the urine 24 h after repeated BCG instillations, i.e. shortly after immunological activation. The antigen expression of the lymphocytes suggested that they may represent the lymphocytes in the bladder wall. Expression of HLA-DR and IL-2 receptors on lymphocytes indicated activation of T cells by the intravesical BCG treatment. These leucocytes may be useful for functional studies, which are essential to elucidate the actual effector mechanism(s) in the mode of action of BCG against superficial bladder cancer in man.

Key words

BCG Immunotherapy Bladder cancer Urine sediment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adolphs HD, Schwabe HW, Helpap B, Volz C (1984) Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis. Urol Res 12: 129Google Scholar
  2. 2.
    Antony VB, Sahn SA, Antony AC, Repine JE (1985) Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest 76: 1514Google Scholar
  3. 3.
    Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Detection of urinary TNF, IL-1, and IL-2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2: 175Google Scholar
  4. 4.
    Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990) Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53Google Scholar
  5. 5.
    De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer: a flow cytofluorometric analysis. Urol Res 1: 45Google Scholar
  6. 6.
    De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Induction of urinary IL-1, IL-2, IL-6, and TNF during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol Immunother (in press)Google Scholar
  7. 7.
    Debruyne FMJ, Denis L, Van Der Meijden APM (eds) (1989) EORTC Genitourinary Group Monograph: 6. BCG in superficial bladder cancer. Prog Clin Biol Res 310Google Scholar
  8. 8.
    De Jong WH, Steerenberg PA, Ruitenberg EJ (1987) Bacillus Calmette-Guérin (BCG) and its use for cancer immunotherapy. In: Den Otter W, Ruitenberg EJ (eds) Tumor immunology — mechanisms, diagnosis, therapy. Elsevier, Amsterdam, p 283Google Scholar
  9. 9.
    De Jong WH, De Boer EC, Van Der Meijden APM, Vegt P, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1990) Presence of interleukin-2 in urine after intravesical treatment of superficial bladder cancer patients with bacillus Calmette-Guérin. Cancer Immunol Immunother 31: 182Google Scholar
  10. 10.
    De Jong WH, De Boer EC, Van Der Meijden APM, Steerenberg PA, Debruyne FMJ (1991) Intravesical BCG administration in the guinea pig: II. Immunohistochemical characterization of cellular infiltrate after one or two cycles of intravesical BCG. Virchows Arch [B] (in press)Google Scholar
  11. 11.
    Gerrard TL, Cohen DJ, Kaplan AM (1981) Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 66: 483Google Scholar
  12. 12.
    Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 36: 970Google Scholar
  13. 13.
    Hanna MG Jr, Snodgrass MJ, Zbar B, Rapp HJ (1973) Histopathology of tumor regression after intralesional injection ofMycobacterium bovis: IV. Development of immunity to tumor cells and BCG. J Natl Cancer Inst 51: 1897Google Scholar
  14. 14.
    Herberman RB, Reynolds CW (1986) Mechanisms of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 4: 651Google Scholar
  15. 15.
    Holzer TJ, Kizlaitis L, Vachula M, Weaver CW, Andersen BR (1988) Human phagocytic cell responses tomycobacterium leprae andMycobacterium bovis bacillus Calmette-Guérin. J Immunol 141: 1701Google Scholar
  16. 16.
    Kleinerman ES, Herberman RB (1984) Tumoricidal activity of human monocytes: evidence for cytolytic function distinct from that of NK cells. J Immunol 133: 4Google Scholar
  17. 17.
    Mitchell MS, Murahata RI (1985) Modulation of immunity by bacillus Calmette-Guérin (BCG). In: Mitchell MS (ed) The modulation of immunity. Pergamon, UK, p 275Google Scholar
  18. 18.
    Mukherji B, Charaborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116: 33Google Scholar
  19. 19.
    Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63: 264Google Scholar
  20. 20.
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248Google Scholar
  21. 21.
    Ratliff TL (1989) Mechanisms of action of intravesical BCG for bladder cancer. EORTC Genitourinary Group Monograph: 6. BCG in superficial bladder cancer. Prog Clin Biol Res 310: 107Google Scholar
  22. 22.
    Ratliff TL, Gillen DP, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137: 155Google Scholar
  23. 23.
    Schamhart DHJ, Kurth K (1990) Detection of urinary IL-6 during intravesical BCG therapy (abstract). J Urol 143: 321 AGoogle Scholar
  24. 24.
    Shapiro A, Lijovetzki G, Pode D (1988) Changes of the mucosal architecture and of urine cytology during BCG treatment. World J Urol 6: 61Google Scholar
  25. 25.
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL (1988) Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J Urol 139: 941Google Scholar
  26. 26.
    Van Der Meijden APM, De Jong WH, De Boer EC, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1989) Immunological aspects of intravesical administration of bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res 17: 47Google Scholar
  27. 27.
    Van der Meijden APM, Steerenberg PA, Van Hoogstraaten IMW, Kerckhaert JA, Schreinemachers LMH, Harthoorn-Lasthuizen ET, De Jong WH, Debruyne FMJ, Ruitenberg EJ (1989) Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 28: 287Google Scholar
  28. 28.
    Van Der Meijden APM, Debruyne FMJ, Steerenberg PA, De Jong WH (1989) BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer: rationale and design of the trial of the southeast co-operative urological group, The Netherlands. EORTC Genitourinary Group Monograph: 6. BCG in superficial bladder cancer. Progr Clin Biol Res 310: 11Google Scholar
  29. 29.
    Weiner RS, Linn R, Wasjman Z, Hackett RL (1989) Identification of T subpopulation in human bladder washings during a six week course of intravesical BCG (abstract). J Urol 141: 291 AGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • E. C. De Boer
    • 1
  • W. H. De Jong
    • 1
  • A. P. M. Van Der Meijden
    • 2
    • 3
  • P. A. Steerenberg
    • 1
  • J. A. Witjes
    • 2
  • P. D. J. Vegt
    • 4
  • F. M. J. Debruyne
    • 2
  • E. J. Ruitenberg
    • 5
    • 6
  1. 1.Laboratory for PathologyNational Institute of Public Health and Environmental ProtectionBilthovenThe Netherlands
  2. 2.Department of UrologyUniversity Hospital NijmegenNijmegenThe Netherlands
  3. 3.Department of UrologyGrootziekengasthuis, 's-HertogenboschThe Netherlands
  4. 4.Department of UrologySt. Elisabeth HospitalLeiderdorpThe Netherlands
  5. 5.Institute of Infectious Diseases and Immunology, Faculty of Veterinary MedicineState University UtrechtThe Netherlands
  6. 6.Central Laboratory of the Netherlands Red Cross Blood Transfusion ServiceAmsterdamThe Netherlands

Personalised recommendations